·SEC EDGARLow
Sherbet Eric sold (to issuer) $1.1M of IQV
Sherbet Eric (See Remarks) sold (to issuer) 3,990 shares of IQVIA HOLDINGS INC. (IQV) at $278.74 ($1.11M total) on 2026-11-09.
StockNYSE · US · USDHealthcare · Diagnostics & Research
$IQV
IQVIA HOLDINGS INC.
IQVIA provides clinical research services, commercial insights and healthcare intelligence to life sciences and healthcare organizations. Its clients include pharmaceutical, biotechnology, medical device and diagnostic companies, as well as payers, providers, government agencies, researchers, distributors and pharmacies. IQVIA combines healthcare data, analytics, technology and domain expertise to support drug development and commercialization, real-world evidence research, clinical and commercial operations, and patient and healthcare provider engagement. Its offerings include cloud-based software and data products, consulting and analytics, clinical trial management and laboratory services, contract sales teams, medical services and patient support programs. IQVIA operates through Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, with reportable segments changing effective January 1, 2026, to Commercial Solutions and Research & Development Solutions. It earns money by providing services, data, software and technology platforms to clients. IQVIA is headquartered in Durham, North Carolina, and has approximately 93,000 employees in over 100 countries.
AlphAI earnings readThird quarter 2026 · OCT 27IQVIA Reports Third-Quarter 2026 ResultsVerdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $IQVvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $IQV in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $2.4M 2 txs
Sherbet Eric2× · $2.4M
10b5-1 share of filings0%
Top stories · $IQVMore →
·SEC EDGAR
Sherbet Eric sold $1.2M of IQV
Sherbet Eric (See Remarks) sold 4,446 shares of IQVIA HOLDINGS INC. (IQV) at $278.83 ($1.24M total) on 2026-11-09.
·finance.yahoo.com
5 revealing analyst questions from IQVIA’s Q3 earnings call
IQVIA reported Q3 revenue of $4.43 billion, beating estimates by 1.5%, with adjusted EPS of $3.34, a 2% beat. The company raised full-year revenue guidance to $17.43 billion. Analysts discussed AI-driven workflows, margin improvements, and clinical bookings during the earnings call. CEO Ari Bousbib highlighted proprietary data and life sciences expertise as key differentiators.
IQV sentiment & insider activity
Recent IQV coverage spans financial news, earnings and insider activity.
In the last 30 days, IQV insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($2.4M). The most active reporter was Sherbet Eric, See Remarks, with 2 filings.
What's driving IQV
Insider sale by a company officer may signal personal confidence level and could pressure the stock modestly.
The insider sale may create modest selling pressure on IQV.
Earnings beat and modest guidance raise suggest near-term upside.
Analyst upgrade suggests upside potential for IQVIA.
Analyst maintains bullish stance, suggesting modest upside potential.
AlphAI scores every news story that mentions IQV with an AI model for sentiment and relevance, and aggregates insider trades from IQVIA HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $IQV
Score
Sherbet Eric sold (to issuer) $1.1M of IQV
Sherbet Eric (See Remarks) sold (to issuer) 3,990 shares of IQVIA HOLDINGS INC. (IQV) at $278.74 ($1.11M total) on 2026-11-09.
Sherbet Eric sold $1.2M of IQV
Sherbet Eric (See Remarks) sold 4,446 shares of IQVIA HOLDINGS INC. (IQV) at $278.83 ($1.24M total) on 2026-11-09.
5 revealing analyst questions from IQVIA’s Q3 earnings call
IQVIA reported Q3 revenue of $4.43 billion, beating estimates by 1.5%, with adjusted EPS of $3.34, a 2% beat. The company raised full-year revenue guidance to $17.43 billion. Analysts discussed AI-driven workflows, margin improvements, and clinical bookings during the earnings call. CEO Ari Bousbib highlighted proprietary data and life sciences expertise as key differentiators.
TD Cowen maintains IQVIA Holdings at Buy, raises price target to $307 from $288
TD Cowen reaffirmed its Buy rating for IQVIA Holdings and increased its price target to $307 from $288. The new target suggests a 10% upside from the last close of $279.04. Recent analyst notes have set price targets for the company between $303 and $346.
Truist Securities maintains Buy rating on IQVIA Holdings, $346 price target
Truist Securities kept a Buy rating on IQVIA Holdings with a $346 price target, implying 27.4% upside. The company reported strong financials, beating revenue estimates by $60M and raising guidance by $50M. Analysts cite robust demand in R&D and Commercial Solutions as growth drivers.
IQVIA Reports Third-Quarter 2026 Results
IQVIA HOLDINGS INC. (IQV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IQVIA Reports Third-Quarter 2026 Results • Revenue $4,428 million, up 8.0% year-over-year, up 8.6% at constant currency • GAAP Net Income $350 million, Adjusted EBITDA $1,032 million, up 8.7% year-over-year • GAAP Diluted Earnings per Share $2.10, Adjusted Diluted Ea
Clinical research provider IQVIA raises 2026 sales forecast to $17.35B–$17.5B
IQVIA (IQV) reported Q3 2026 revenue of $4.428B, up 8% YoY, and raised its 2026 sales forecast to $17.35B-$17.5B. The company also increased guidance for Adjusted EBITDA and Adjusted Diluted EPS. IQVIA's CEO highlighted strong market demand and execution, including AI-powered solutions and clinical trial bookings. The company will host an Investor Day on December 1, 2026.
IQVIA’s own noncompete clauses torpedo its lawsuit against rival Syneos
IQVIA's lawsuit against former employees and Syneos Health was dismissed because it was filed in the wrong state, violating its own agreements requiring Delaware courts. The case involved allegations of breached noncompete clauses and unfair competition. IQVIA may refile in Delaware.
Locking in Gains: Portfolio Discipline Triggers IQVIA Holding (IQV) Trim After Q2 Beat
Broyhill Asset Management's Q3 2026 investor letter reported a 0.3% decrease in its Broyhill Equity Composite, underperforming the MSCI All Country World Index. IQVIA Holdings (IQV) was a top contributor, with Q2 results beating expectations and guidance raised. IQV shares rose 12% post-earnings, and Broyhill trimmed its position. IQV closed at $278.32, up 26.21% year-over-year.
From Headwinds to Full Valuation: The Disciplined Exit of IQVIA Holdings (IQV)
Vulcan Value Partners sold IQVIA Holdings (IQV) in Q3 2026, citing its share price nearing their estimated value. IQV, a healthcare research services provider, saw its stock rise 26.21% over the past year, closing at $278.32 on October 22, 2026. The firm praised IQV's earnings, cash flow, and management but exited to invest in more discounted opportunities.